<DOC>
	<DOCNO>NCT02336477</DOCNO>
	<brief_summary>Treatment strategy non-dystrophic myotonia base selective case report , clinical experience theoretical benefit . Presently , promise antimyotonic medication mexiletine ( MEX ) manufacturing stop . The propose randomized , double-blind , placebo-controlled , crossover trial design : 1. study safety efficacy mexiletine treatment non-dystrophic myotonia 2. validate electromyographic test standardize outcome measure myotonia 3. ass reliability validity new clinical rating scale myotonia</brief_summary>
	<brief_title>Mexiletine Non Dystrophic Myotonias</brief_title>
	<detailed_description>A . Specific aims Treatment strategy non-dystrophic myotonia base selective case report , clinical experience theoretical benefit . Presently , promise antimyotonic medication mexiletine ( MEX ) manufacturing stop . The propose randomized , double-blind , placebo-controlled , crossover wash-out trial design : - study safety efficacy mexiletine treatment non-dystrophic myotonia - validate electromyographic test standardize outcome measure myotonia - ass reliability validity new clinical rating scale myotonia B . Research design Because differ phenotype , 12 Paramyotonia Congenita 12 Myotonia Congenita subject enrol stratified trial C. Outcome variables 1. primary outcome variable : score stiffness severity self-assessment scale ( 100 mm VAS ) measure baseline , end phase I phase II . 2. secondary outcome measure : - efficacy : - standardized EMG measure repetitive short exercise test cold long exercise test - chair test : time need stand chair , walk around sit - severity disability scale myotonia validate ) - quality life scale ( INQOL ) - rate drop-outs - safety : - adverse event frequency severity - EKG D. Perspectives It anticipated trial : 1. provide data justify recommendation treatment strategy myotonic patient 2. provide data justify AFSAPPS regulatory approval mexiletine treatment myotonia order guarantee availability drug patient 3. develop standardize diagnostic treatment assessment non-dystrophic myotonia</detailed_description>
	<mesh_term>Myotonia</mesh_term>
	<mesh_term>Myotonia Congenita</mesh_term>
	<mesh_term>Myotonic Disorders</mesh_term>
	<mesh_term>Mexiletine</mesh_term>
	<criteria>Inclusion criterion : Genetically definite MC PC . Male female participant , age 18 65 able comply study condition . Participants experience myotonic symptom severe enough justify treatment . The severity evaluate : Clinical criterion : myotonia consider severe involves least two segment ( upper limb , low limb face ) Disabling criterion : myotonia consider severe patient notice impact least 3 7 daily activity list disable section clinical myotonia scale ( Annex 2 ) . Thus , patient experience myotonic symptom severe enough justify treatment myotonia involve least two segment impact least 3 daily activity . Participants drug naive receiving mexiletine Effective dosage agree stop treatment least four day inclusion . Pregnancy : Women : nonchildbearing potential ( i.e. , postmenopausal Surgically sterile ) must use medically accepted contraceptive regimen ; pregnancy test ensure pregnant . Normal cardiac exam perform cardiologist include EKG , Cardiac ultrasound ( do within 3 month trial ) . Exclusion criterion : Intercurrent event could interfere muscle function ( infection , trauma , fracture , â€¦ ) Coincidental renal , hepatic , respiratory , thyroid , neuromuscular disease heart disease contraindicate mexiletine interfere clinical evaluation . Use following medication interfere muscle function : diuretic , anti epileptic ( sodium channel blocker ) , antiarrhythmic , corticosteroid , betablockers , Allergy mexiletine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>non-dystrophic myotonia</keyword>
	<keyword>paramyotonia congenita</keyword>
	<keyword>myotonia congenita</keyword>
	<keyword>Mexiletine</keyword>
	<keyword>Randomized clinical trial</keyword>
</DOC>